Take­da ax­es gene ther­a­py deal with Po­sei­da Ther­a­peu­tics amid broad­er re­think

Less than two years af­ter Take­da inked a col­lab­o­ra­tion with Po­sei­da Ther­a­peu­tics to de­vel­op six liv­er-di­rect­ed and hematopoi­et­ic stem cell-di­rect­ed in vi­vo gene ther­a­pies, Take­da will end the part­ner­ship on Ju­ly 30, the com­pa­ny con­firmed to End­points News.

The breakup is not un­ex­pect­ed, com­ing on the heels of Take­da’s April an­nounce­ment that it planned to stop dis­cov­ery and pre­clin­i­cal work in AAV gene ther­a­py, as well as re­search and pre­clin­i­cal work on rare hema­tol­ogy. A rep­re­sen­ta­tive for Take­da con­firmed that the part­ner­ship end­ed be­cause of the com­pa­ny’s de­ci­sion to stop that work.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.